Nicholson Contributed to "Mortgage and Asset Backed Securities Litigation Handbook"
04 December 2012
Partner Jill Nicholson contributed the section titled “Lender and Originator Bankruptcy” in Thomson Reuters Westlaw’s book “Mortgage and Asset Backed Securities Litigation Handbook.”
Book description:
Mortgage and Asset Backed Securities Litigation Handbook provides in-depth guidance through the complex issues surrounding a securitized mortgage. In this title you’ll find essential information to effectively litigate an asset or mortgage-backed securities case and coverage of other critical issues, including:
- Securitization and how it affects the claims by or against a client
- Borrower litigation
- Collection and foreclosure
- Rating agency claims
- Bankruptcy
- Lender liability
- Certificate holder claims
- Loan origination and servicing
- Trust representation
Recent caselaw, sample deal documents, a thorough glossary, a table of cases, and an index are included.
Click here to learn more about the book.
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”